Lonza raises full-year core profit margin guidance

• Core EBITDA margin target increased to 33-34% of sales for the full year, up from the previous guidance of 'more than 32%'
• The upgrade reflects strong operational performance and positive contributions from growth projects that are reaching maturity
• Lonza is the world's largest dedicated contract drug manufacturer, specializing in cell and gene therapy production

Lonza Raises Full-Year Core Profit Margin Guidance

Key Development:

Swiss pharmaceutical manufacturer Lonza, the world's largest contract drug manufacturer, has upgraded its full-year core profit margin guidance on July 22. The company now expects its core EBITDA (earnings before interest, taxes, depreciation, and amortization) margin to reach between 33% and 34% of sales, up from the previous target of more than 32%.

Drivers of Growth:

The upward revision is attributed to strong operational execution and contributions from maturing growth projects. This indicates that Lonza's strategic investments are beginning to deliver tangible financial results.

Company Profile:

Lonza operates the world's largest dedicated cell and gene therapy facility, located in Houston, Texas, which opened in April 2018. The company specializes in contract manufacturing for pharmaceutical clients, a critical segment in the biopharma supply chain.

Market Implications:

The guidance raise suggests robust demand for contract drug manufacturing services and effective cost management. This positive development comes amid a broader pharmaceutical industry trend toward outsourcing manufacturing to specialized contractors. The improved margin outlook—representing a potential 2 percentage point increase from the previous guidance—signals stronger-than-expected business performance in the current year.

For investors, the announcement reflects Lonza's operational efficiency and its ability to capitalize on growth opportunities in the cell and gene therapy sectors, which are experiencing significant expansion. The margin improvement could indicate pricing power and operational leverage as the company scales its newer facilities and projects.